Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.3 (
collagenase
)
18,340
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The production of
collagenase
and collagenase inhibitor (TIMP) by various
intracranial tumors
(25 meningiomas, eight gliomas, seven metastases, four pituitary adenomas, and five others) was studied in short-term organ culture. While meningiomas produced negligible amounts of
collagenase
, two metastatic carcinomas of bronchial and breast origin produced significant amounts of the enzyme. Cultures of dura from an invasive meningioma and of bone invaded by a meningioma also produced
collagenase
. In varying amounts, TIMP was detected in culture media from most of the tumors studied; invasive tumors tended to produce less TIMP than noninvasive tumors. The results are discussed in relation to current views on tissue degradation and mechanisms of tumor invasion.
...
PMID:Production of collagenase and inhibitor (TIMP) by intracranial tumors and dura in vitro. 631 67
We explored the clinical and pathological impact of epidermal growth factor receptor (EGFR) extracellular domain missense mutations. Retrospective assessment of 260 de novo glioblastoma patients revealed a significant reduction in overall survival of patients having tumors with EGFR mutations at alanine 289 (EGFR
A289D/T/V
). Quantitative multi-parametric magnetic resonance imaging analyses indicated increased tumor invasion for EGFR
A289D/T/V
mutants, corroborated in mice bearing
intracranial tumors
expressing EGFR
A289V
and dependent on ERK-mediated expression of
matrix metalloproteinase-1
. EGFR
A289V
tumor growth was attenuated with an antibody against a cryptic epitope, based on in silico simulation. The findings of this study indicate a highly invasive phenotype associated with the EGFR
A289V
mutation in glioblastoma, postulating EGFR
A289V
as a molecular marker for responsiveness to therapy with EGFR-targeting antibodies.
...
PMID:Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. 2999 Apr 98
